On October 19, 2020 Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, reported the successful closing of a € 22 m (~US$ 26 m) Series B financing round (Press release, Evotec, OCT 19, 2020, View Source;announcements/press-releases/p/topas-therapeutics-raises-eur-22-m-us-26-m-in-series-b-financing-5987 [SID1234568608]). New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas’ existing investors . The funding will be used to advance the Company’s proprietary pipeline based on the Topas Particle Conjugates technology platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!